Paltan Plant FPP Manufacturing Sites. Pyeongtaek Plant Bio Plant Cepha Plant. Hanmi Fine Chem API Business

Transcription

1

2 2

3

4 4

5 Paltan Plant FPP Manufacturing Sites ODM Partnership with global partners : MSD, Sanofi, etc The New Global Smart Plant completed and received operation approval in Dec 2016 Annual capsule production capacity : 2B max. 10B Pyeongtaek Plant Bio Plant Cepha Plant Production of investigational new biologics for global studies Second Bio Plant under construction for global clinical trials and commercialization of LAPSCOVERY based new biologics Certified by PIC/S Hanmi Fine Chem API Business 30% M/S of European cephalosporin antibiotics API market FDA(US), BSG(GER), TGA(AUS), PMDA(JPN), EDQM(EU), MHRA(GB) GMP received 5

6 PAST PRESENT FUTURE Strong cash flow from traditional pharma business through inhouse FCD/IMD products & generics Heavy investment in innovative R&D from early 2000s Robust pipeline from in-house, as well as external R&D Maintain leadership in core businesses in Korea & China Investment in areas of high-growth potential Become a global R&D powerhouse through continuous new drug discovery & development in core therapeutic areas To achieve significant growth through innovative new drugs 6

7

8 1,500 Sales R&D 14.2% 1, , % % 20.0% %

9 9

10 AGLYCOSYLATED FC AGLYCOSYLATED FC Therapeutic Agent : Natural/Unnatural peptide Flexible Linker :Reduce Immunogenicity Minimized loss of activity No loss of FcRn binding Aglycosylated Fc : Increase solubility 10

11 Next-generation bi-specific antibody platform technology Discovery by Beijing Hanmi with dual immunotherapy & targeted therapy Immune cell Tumor cell Key Features Redirect immune cells to tumor cells P E N O D Y Natural IgG-like bi-specific antibody format Good stability and high production efficiency T B Seeking collaboration opportunities A M (PENTAMBODY + Novel target) 11

12 Redirect immune cells to tumor cells Better anti-tumor activity compared to combination Pentambody applied PD-1/HER2 BsAb Cell-to-cell association (%) using SK-BR-3 and CHO-PD1 cells by FACS 1 Pentambody applied PD-1/PD-L1 BsAb Cell cytotoxicity assay using PD-L1 expressed NSCLC cell 2 Anti-PD-L1 mab: IC 50 >2,000 pm Anti-PD-1 mab: IC pm Combination: IC pm PD-1/PD-L1 BsAb (BH2941): IC pm 1 HER2 positive SK-BR-3 stained with CFSE, CHO-PD1 stained with PKH26, Test article 100nM, 30min; 2 E (activated hpbmc) : T (HCC827) = 20 : 1, 72hr 12

13 Pre-Clinical Phase 1 Phase 2 Phase 3 SANOFI LAPS Insulin Combo HM14220 Diabetes FLT3 Inhibitor HM43239 AML JANSSEN LAPS GLP/GCG HM12525A Diabetes/Obesity SANOFI LAPS Exd4 Analog Efpeglenatide Diabetes/Obesity SPECTRUM Rolontis Eflapegrastim Neutropenia LAPS Triple Agonist HM15211 Obesity, NASH AJOU Univ GMB Stem Cell Therapy HM21001 Glioblastoma LAPS Insulin/ LAPS Insulin Analog HM12460A/HM12470 Diabetes SPECTRUM/LUYE Pan-HER Inhibitor Poziotinib Solid tumor ATHENEX Oraxol ** Paclitaxel+HM30181A Breast cancer LAPS Glucagon Analog HM15136 Congenital Hyperinsulinism INNOVENT B PD-1/TAA1 Solid tumor Targeted Immuno-oncology GENENTECH Pan-RAF Inhibitor HM95573 Solid tumor ELI LILLY BTK Inhibitor HM71224 Autoimmune diseases ZAI LAB Olita * Olmutinib NSCLC LAPS ASB HM15450 Mucopolysaccharidosis B PD-1/TAA2 Solid tumor Targeted Immuno-oncology ATHENEX Oratecan Irinotecan+HM30181A Solid tumor ALLEGRO Luminate Integrin inhibitor DME LAPS GLP-2 Analog HM15910 Short Bowel Syndrome B PD-1/TAA3 Solid tumor Targeted Immuno-oncology ATHENEX Src/Tubulin KX2-391 Solid tumor LAPS hgh Efpegsomatropin GH deficiency Diabetes/Obesity Rare Diseases Cancer Autoimmune Diseases Others B Beijing Hanmi 13

14 Launching 2~3 products annually in the domestic market Seeking partners for emerging market business *Incrementally Modified Drug **Fixed Dose Combination 14

15 Strong focus on R&D +500 R&D experts : Ph.D 64, MS mil USD invested in the past decade 29 Programs in Pre-clinical & Clinical Development Partnership & Alliance Broadening global & regional partnership Open innovation strategy China Market Synergy between Beijing Hanmi & Hanmi Korea Competitive R&D supported by global talents Profitable growth through business diversification

16 Est Full Value Chain : R&D to commercialization Beijing R&D center Manufacturing Sales & Marketing R&D staffs 160+ PhD.8, MS. 82 Est. Oct 2008 Animal facility for rodents, beagles, and primates High-tech enterprise certification Focus areas NCE - Auto-immune - Oncology New Biologics - Diabetes - Obesity - Oncology BIO Production - PENTAMBODY GMP sites To provide FPP to Chinese market Sales force 1,000+ About 70% : Doctors and Pharmacists Directly covering 9,000 hospitals and over 150,000 doctors, keeping the No.1 position in pediatric drug market. 16

17 17

18 Strong focus on R&D +500 R&D experts : Ph.D 64, MS mil USD invested in the past decade 29 Programs in Pre-clinical & Clinical Development Partnership & Alliance Broadening global & regional partnership Open innovation strategy China Market Synergy between Beijing Hanmi & Hanmi Korea Competitive R&D supported by global talents Profitable growth through business diversification

19 19

20 20

21 21

22 22

23 23

24 24

25 25

26 26.8% 27.6% 27.4% 27.4% 24.6% 24.4% 25.4% 25.5% 26

27 27

28 -7.9% -6.5% 6.8% 23.6% -21.0% -10.6% 9.9% 25.5% 21.3% 0.8% -22.2% 16.7% 28.6% -10.0% 55.6% 0% 28

29

30 30

31 31

32 32

33